Lifetime prevalence of Type 2 comorbidities in patients with COPD: especially those with higher eosinophilic counts

Study summary

No information provided.

Study identification

• EU PAS number:
  EUPAS1000000792
• Study ID:
  1000000792
• Official title and acronym:
  Lifetime prevalence of Type 2 comorbidities in patients with COPD: especially those with higher eosinophilic counts
• DARWIN EU® study:
  No
• Study countries:
  United Kingdom
• Study description:
  This real-world evidence study employs a retrospective cohort design using data from the OPCRD dataset to compare the prevalence of Type 2 (T2) inflammation-related comorbidities in individuals with COPD and those with T2 asthma. The study population includes three groups: COPD-only, asthma-only, and patients with both COPD and asthma, with further stratification based on blood eosinophil counts. Inclusion criteria require individuals aged 20 and above, diagnosed using spirometry and medical coding, while those with overlapping chronic respiratory conditions (e.g., cystic fibrosis) are excluded. Primary outcomes include the prevalence and incidence of T2 comorbidities, analyzed through lifetime prevalence, pre-diagnosis prevalence, and incidence within five years post-diagnosis. Statistical analyses include descriptive statistics, Poisson regression models for prevalence comparisons, and Kaplan-Meier curves to assess cumulative incidence. Sensitivity analyses will address missing eosinophil data and rounding biases by refining eosinophil count categories. The findings will provide insights into the relationship between eosinophilic inflammation and comorbidities, aiding in personalized treatment approaches for COPD patients with T2 features.
• Study status:
  Planned

Research institutions and networks

Institutions

Observational & Pragmatic Research Institute Pte (OPRI)

United Kingdom

Study timelines

Date when funding contract was signed

Planned:28/01/2025

Study start date

Planned:10/01/2025

Date of final study report

Planned:31/05/2025

Sources of funding

Other public funding (e.g. hospital or university)

More details on funding

University of Exeter

Regulatory

• Was the study required by a regulatory body?:
  Unknown
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable